PDCD1 and cancer: Blocking the interaction between PD-1 and PD- L1 is the aim of anti-PD-1/PD-L1 immunotherapy, therefore its therapeutic effect depends on the expression of PD-1 or PD-L1 in cancer microenvironment (11, 12).